Safety boundary: This page cannot diagnose BPH or prostate cancer, interpret an individual result or recommend delaying care. Urinary retention, heavy bleeding, severe pain, fever with urinary symptoms or rapid deterioration need prompt medical attention.
Direct answer
The useful next step is not to label one result “good” or “bad.” Verify the result and testing conditions, connect it to prior values, medicines and clinical risk, then ask which additional information would materially change the decision.
Decision table
| Factor | What it tells you | What still needs interpretation |
|---|
| Input 1 | Serum PSA value with units and collection date. | Temporary influences, medicines and testing context still matter. |
|---|
| Input 2 | Prostate volume measured by ultrasound or MRI, usually reported in milliliters or cubic centimeters. | Different imaging methods, segmentation and timing can produce different estimates. |
|---|
| Formula | PSA density = PSA (ng/mL) ÷ prostate volume (mL). | The output is commonly expressed as ng/mL per mL. |
|---|
| Potential value | Connects PSA production to the amount of prostate tissue measured. | May contribute to risk refinement with MRI, history and other findings. |
|---|
| Key limitation | A calculated number can look more precise than the underlying measurements are. | Volume error, inflammation, retention and medication effects can shift the result. |
|---|
| Decision boundary | No result proves BPH or cancer. | A clinician should explain how density changes the planned pathway, if at all. |
|---|
Transparent calculator: arithmetic only
This calculator performs division only. It does not validate whether the two inputs belong together, account for finasteride or dutasteride, assess MRI findings, or recommend biopsy. Use the original reports and have a clinician interpret the result.
Why measurement method matters
Prostate volume may come from transrectal ultrasound, abdominal ultrasound or MRI. Shape assumptions and segmentation can change the estimate. A density calculated from an old volume and a new PSA may describe neither clinical episode accurately.
Consultation checklist
- Use PSA and volume values with dates from original reports.
- Confirm the imaging method and whether the prostate was completely measured.
- Ask whether retention, inflammation or recent instrumentation could affect the PSA.
- List finasteride or dutasteride use and its duration.
- Ask how MRI findings interact with density.
- Ask whether recalculation would change any decision.
Shortcuts to reject
- Using an estimated “walnut size” instead of measured volume.
- Combining an old scan with a new PSA without review.
- Treating a threshold as a diagnosis.
- Ignoring uncertainty in both numerator and denominator.
How to use evidence without overreading it
Guidelines describe how groups of patients may be evaluated; prescribing information explains known drug effects; studies report outcomes in defined populations. None can supply the missing details of an individual medical history. Check the evidence date, population, exclusions, assay or imaging method, and the decision the source was designed to support.
UriSmooth does not diagnose prostate disease and is not presented as an alternative to repeat testing, imaging, biopsy or treatment. The commercial owner of this site benefits from supplement sales, so this testing cluster deliberately uses clinician-discussion actions rather than a product CTA.
Sources and review status
Sources checked September 22, 2026. These drafts remain outside the XML sitemap until a qualified reviewer verifies current guidance, labels, claims and patient-facing balance. Source organizations do not endorse UriSmooth.
Frequently asked questions
1. What should I know about the PSA-density formula?
The PSA-density formula links PSA to measured prostate volume. Check the imaging method and dates, then treat the calculation as one risk input—not proof of BPH, cancer or the need for a procedure.
2. What should I know about prostate volume units?
Prostate volume units links PSA to measured prostate volume. Check the imaging method and dates, then treat the calculation as one risk input—not proof of BPH, cancer or the need for a procedure.
3. What should I know about ultrasound versus MRI volume?
Ultrasound versus MRI volume can add anatomical or risk information, but it does not make every diagnosis. Ask what result would change the plan, whether the image is current and how a negative or uncertain finding will be handled.
4. What should I know about an old prostate measurement?
An old prostate measurement belongs in a defined clinical decision, not a keyword shortcut. Ask what it measures, what it misses, whether it applies to your situation and exactly how it would change the next step.
5. What should I know about finasteride or dutasteride?
Finasteride or dutasteride must be interpreted from the actual drug, dose, indication, start date and adherence history. Do not stop treatment or apply a generic correction formula without the prescribing clinician.
6. What should I know about urinary retention?
Urinary retention should not be routed through an online PSA explainer. Seek prompt clinical advice; inability to urinate, severe pain, fever with urinary symptoms, heavy bleeding or rapid deterioration may require urgent care.
7. What should I know about prostatitis?
Prostatitis can affect PSA context or measurement. Record timing honestly and ask whether the result should be confirmed after the relevant condition resolves; do not self-treat merely to change a test.
8. What should I know about MRI interpretation?
MRI interpretation can add anatomical or risk information, but it does not make every diagnosis. Ask what result would change the plan, whether the image is current and how a negative or uncertain finding will be handled.
9. What should I know about a density cutoff?
A density cutoff links PSA to measured prostate volume. Check the imaging method and dates, then treat the calculation as one risk input—not proof of BPH, cancer or the need for a procedure.
10. What should I know about biopsy decisions?
Biopsy decisions is a tissue-sampling decision, not an automatic consequence of one PSA value. For psa density vs psa: add prostate volume without pretending to diagnose, ask how repeat testing, overall risk, MRI or biomarkers change the expected benefit and harms of biopsy.
11. What should I know about calculator limitations?
Calculator limitations can look precise while hiding uncertainty. Use the original report, prior values, medicines, prostate findings and personal risk context; this page does not turn a number into a diagnosis.
12. What should I know about repeating the calculation?
Repeating the calculation depends on why the test was ordered and whether temporary influences or concerning findings are present. A clinician should set the interval; repeating a newly elevated result can be appropriate, but delay is not automatically safe in every case.
Related decisions
Return to the PSA and diagnostic-test hub, review possible next-step discussions after an elevated PSA, or prepare for tests before BPH treatment.